- Home
- AGIO vs GOF Comparison
AGIO vs GOF Comparison
Compare AGIO & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- GOF
- Stock Information
- Founded
- AGIO 2007
- GOF 2006
- Country
- AGIO United States
- GOF United States
- Employees
- AGIO N/A
- GOF N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- GOF Finance/Investors Services
- Sector
- AGIO Health Care
- GOF Finance
- Exchange
- AGIO Nasdaq
- GOF Nasdaq
- Market Cap
- AGIO 2.4B
- GOF 2.3B
- IPO Year
- AGIO 2013
- GOF N/A
- Fundamental
- Price
- AGIO $35.42
- GOF $15.25
- Analyst Decision
- AGIO Buy
- GOF
- Analyst Count
- AGIO 7
- GOF 0
- Target Price
- AGIO $56.33
- GOF N/A
- AVG Volume (30 Days)
- AGIO 1.1M
- GOF 789.2K
- Earning Date
- AGIO 02-13-2025
- GOF 01-01-0001
- Dividend Yield
- AGIO N/A
- GOF 15.42%
- EPS Growth
- AGIO N/A
- GOF N/A
- EPS
- AGIO 11.80
- GOF N/A
- Revenue
- AGIO $32,871,000.00
- GOF N/A
- Revenue This Year
- AGIO $33.38
- GOF N/A
- Revenue Next Year
- AGIO $163.06
- GOF N/A
- P/E Ratio
- AGIO $3.00
- GOF N/A
- Revenue Growth
- AGIO 36.79
- GOF N/A
- 52 Week Low
- AGIO $20.96
- GOF $10.96
- 52 Week High
- AGIO $62.58
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- AGIO 28.75
- GOF 36.77
- Support Level
- AGIO $37.20
- GOF $15.02
- Resistance Level
- AGIO $44.46
- GOF $15.81
- Average True Range (ATR)
- AGIO 4.27
- GOF 0.17
- MACD
- AGIO -2.06
- GOF -0.08
- Stochastic Oscillator
- AGIO 1.06
- GOF 23.71
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.